CCA
XERS icon

Catalyst Capital Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

Catalyst Capital Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-373
Closed -$7K – 540
2018
Q2 		$7K Buy
+373
New +$7.25K ﹤0.01% 409

Other funds holding XERS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Catalyst Capital Advisors's XERS Position: Q3 2018 in Review

Catalyst Capital Advisors sold out of Xeris Biopharma Holdings (XERS) in Q3 2018, closing a stake of 373 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in XERS in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 36 funds tracked by Wall St. Rank hold XERS as of Q3 2018.

  • Catalyst Capital Advisors reported no remaining Xeris Biopharma Holdings position as of Q3 2018 after selling out during the quarter.
  • Catalyst Capital Advisors sold 373 Xeris Biopharma Holdings shares in Q3 2018, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Xeris Biopharma Holdings in Q2 2018 and held it in 1 quarter.
  • Catalyst Capital Advisors's Xeris Biopharma Holdings position peaked at $7K in Q2 2018.
  • 36 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2018.

Based on Catalyst Capital Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.